Is New Surgical Tech Clearance And EU IOL Launch Altering The Investment Case For Bausch + Lomb (BLCO)?

• Bausch + Lomb recently received U.S. FDA 510(k) clearance for its Bi-Blade+ dual-port vitrectomy cutter and Adaptive Fluidics upgrade on the Stellaris Elite system, and began European commercialization of the preloaded enVista Envy full range of vision intraocular lenses.
• Together, these launches expand the company’s retinal and cataract surgery portfolio with technologies aimed at improving surgical efficiency, intraocular pressure stability and visual outcomes for patients.
• Next, we’ll examine how the Bi-Blade+ and Adaptive Fluidics approvals may reinforce Bausch + Lomb’s existing investment narrative in surgery.

Find 62 companies with promising cash flow potential yet trading below their fair value.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe its three engines Pharma, Vision Care and Surgery can compound together while the company moves from losses toward sustainable profitability. In the near term, a key catalyst is execution in higher margin surgical products, while the biggest risk is that rising competition and pricing pressure across dry eye, contact lenses and premium IOLs caps revenue growth. The new retina and IOL launches appear directionally supportive but not individually transformative near term.

Against that backdrop, the FDA clearance of Bi-Blade+ and Adaptive Fluidics looks most relevant. It incrementally strengthens the Stellaris Elite platform in retinal surgery, a higher value part of the Surgical segment that many investors already see as important for margin mix. Seen alongside the European rollout of the preloaded enVista Envy IOL family, it highlights how Bausch + Lomb is leaning on surgical innovation to support the existing thesis around premium procedure volumes and mix.

Yet while these launches speak to innovation, investors should also weigh the risk that intensified pricing pressure across dry eye, lenses and premium IOLs could quietly limit how much of that innovation actually reaches the bottom line...

Read the full narrative on Bausch + Lomb (it's free!)

Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from -$305.0 million.

Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Bausch + Lomb could reach about US$6.0 billion in revenue and roughly US$243 million in earnings by 2028, which is far more bullish than consensus. In light of the Bi-Blade+, Adaptive Fluidics and Envy updates, you may find those targets either more plausible or too aggressive, especially if you worry about rising competition and pricing pressure in core categories.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com